Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study.

Sizheng Steven ZhaoKimme HyrichZenas YiuAnne BartonJohn Bowes

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

We provide supportive genetic evidence that IL-13i is linked to increased risk of PsA and psoriasis. Physicians prescribing IL-13 inhibitors should be vigilant for these adverse events.

Keyphrases

primary care
prostate cancer
rheumatoid arthritis
genome wide
ankylosing spondylitis
radical prostatectomy
systemic lupus erythematosus